Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Apr 1;63(1):91-103.
doi: 10.1002/pros.20162.

Establishment and characterization of a human primary prostate carcinoma cell line, HH870

Senthamil R Selvan  1 , Andrew N Cornforth, Nagesh P Rao, Yvonne A Reid, Patric M Schiltz, Ray P Liao, David T Price, F Scott Heinemann, Robert O Dillman
Affiliations

Establishment and characterization of a human primary prostate carcinoma cell line, HH870

Senthamil R Selvan et al. Prostate. .

Abstract

Background: Development of new therapeutic modalities for human prostate carcinoma has been impeded by a lack of adequate in vitro and in vivo models. Most in vitro studies have been carried out using a limited number of human prostate cancer cell lines that are mostly derived from metastatic tumors sites or are immortalized.

Methods: Characterization of the prostate cancer cell line, HH870, included description of morphology, determination of doubling time, response to androgens, immunocytochemistry, and immunoblotting of proteins known to be associated with prostate carcinoma, karyotyping, fluorescence in situ hybridization (FISH), DNA profiling, and growth as xenograft in athymic rodents.

Results: HH870 expresses various epithelial marker antigens that correlate with known basic immunostaining profiles of prostate adenocarcinoma, although the cell line does not express PSA, PSMA, or PAP. HH870 exhibits complex chromosomal abnormalities and harbors no immortalizing HPV, BKV, JCV, and SV40 DNA.

Conclusions: We report the successful establishment and characterization of a new long-term primary human prostate tumor cell line HH870.

PubMed Disclaimer

Publication types